The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations

Journal of Applied Genetics

Volumn 55, Issue 2, 2014, Pages 163-171

  Sominsky, Sophia ^a   Korostishevsky, Michael ^a   Kurnik, Daniel ^a,c   Aklillu, Eleni ^b   Cohen, Yoram ^c   Ken Dror, Gie ^a   Loebstein, Ronen ^a,c   Halkin, Hillel ^a,c   Gak, Eva ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Allele frequencies; Gene flow; Haplotype analysis; Population genetics; Warfarin (Coumarin) resistance

Indexed keywords

VITAMIN K EPOXIDE REDUCTASE; WARFARIN; GENETIC MARKER; VKORC1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALLELE; ARTICLE; ASHKENAZI JEW; DNA SEQUENCE; ETHIOPIA; ETHNICITY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; NUCLEOTIDE SEQUENCE; PARSIMONY ANALYSIS; PHYLOGENY; POLYMERASE CHAIN REACTION SYSTEM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ETHNIC GROUP; GENETIC MARKER; GENETICS; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ETHIOPIA; ETHNIC GROUPS; GENETIC MARKERS; GENETICS, POPULATION; HAPLOTYPES; HUMANS; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; VITAMIN K EPOXIDE REDUCTASES;

EID: 84899029937     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13353-013-0189-2     Document Type: Article

References (41)

1. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E (2008) VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 111(7): 3903-3904.
2. Atzmon G, Hao L, Pe'er I, Velez C, Pearlman A, Palamara PF, Morrow B, Friedman E, Oddoux C, Burns E, Ostrer H (2010) Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am J Hum Genet 86(6): 850-859.
3. Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J, Rootsi S, Chaubey G, Kutuev I, Yudkovsky G, Khusnutdinova EK, Balanovsky O, Semino O, Pereira L, Comas D, Gurwitz D, Bonne-Tamir B, Parfitt T, Hammer MF, Skorecki K, Villems R (2010) The genome-wide structure of the Jewish people. Nature 466(7303): 238-242.
4. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2): 645-649.
5. D'Andrea G, D'Ambrosio R, Margaglione M (2008) Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev 22(3): 127-140.
6. Dang MT, Hambleton J, Kayser SR (2005) The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 39(6): 1008-1012.
7. El Rouby S, Mestres CA, LaDuca FM, Zucker ML (2004) Racial and ethnic differences in warfarin response. J Heart Valve Dis 13(1): 15-21.
8. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94(4): 773-779.
9. Gong X, Gutala R, Jaiswal AK (2008) Quinone oxidoreductases and vitamin K metabolism. Vitam Horm 78: 85-101. doi: 10. 1016/S0083-6729(07)00005-2.
10. Harrington DJ, Siddiq S, Allford SL, Shearer MJ, Mumford AD (2011) More on: endoplasmic reticulum loop VKORC1 substitutions cause warfarin resistance but do not diminish gamma-carboxylation of the vitamin K-dependent coagulation factors. J Thromb Haemost 9(5): 1093-1095. doi: 10. 1111/j. 1538-7836. 2011. 04249. x.
11. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9(7): 811-818.
12. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8): 753-764. doi: 10. 1056/NEJMoa0809329.
13. Korostishevsky M, Kremer I, Kaganovich M, Cholostoy A, Murad I, Muhaheed M, Bannoura I, Rietschel M, Dobrusin M, Bening-Abu-Shach U, Belmaker RH, Maier W, Ebstein RP, Navon R (2006) Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. Am J Med Genet B Neuropsychiatr Genet 141B(1): 91-95. doi: 10. 1002/ajmg. b. 30212.
14. Kurnik D, Qasim H, Sominsky S, Lubetsky A, Markovits N, Li C, Stein CM, Halkin H, Gak E, Loebstein R (2012) Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thromb Haemost 108(4): 781-788. doi: 10. 1160/TH12-03-0151.
15. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427(6974): 541-544. doi: 10. 1038/nature02254.
16. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT (2008a) Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5): 511-526. doi: 10. 2217/14622416. 9. 5. 511.
17. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N (2008b) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10): 1445-1458. doi: 10. 2217/14622416. 9. 10. 1445.
18. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18): 3827-3834. doi: 10. 1182/blood-2009-12-255992.
19. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109(6): 2477-2480.
20. Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN, Masimirembwa CM (2008) Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 16(7): 780-783. doi: 10. 1038/ejhg. 2008. 49.
21. Mitchell C, Gregersen N, Krause A (2011) Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12(7): 953-963. doi: 10. 2217/pgs. 11. 36.
22. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH (2007) Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8(11): 1535-1544. doi: 10. 2217/14622416. 8. 11. 1535.
23. Moorjani P, Patterson N, Hirschhorn JN, Keinan A, Hao L, Atzmon G, Burns E, Ostrer H, Price AL, Reich D (2011) The history of African gene flow into Southern Europeans, Levantines, and Jews. PLoS Genet 7(4): e1001373. doi: 10. 1371/journal. pgen. 1001373.
24. Ostrer H (2001) A genetic profile of contemporary Jewish populations. Nat Rev Genet 2(11): 891-898.
25. Pavani A, Naushad SM, Rupasree Y, Kumar TR, Malempati AR, Pinjala RK, Mishra RC, Kutala VK (2012) Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J 12(4): 306-311. doi: 10. 1038/tpj. 2011. 4.
26. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22): 2285-2293.
27. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974): 537-541. doi: 10. 1038/nature02214.
28. Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J (2005) Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost 94(4): 780-786.
29. Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE (2007) Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 81(5): 742-747. doi: 10. 1038/sj. clpt. 6100144.
30. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7): 2329-2333.
31. Scott SA, Edelmann L, Kornreich R, Desnick RJ (2008) Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 82(2): 495-500.
32. Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, Patel S, Perry K, Meltzer DO, McLeod HL, Johnson JA (2013) VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost 109(6): 1045-1050. doi: 10. 1160/TH12-10-0789.
33. Shearer MJ, Newman P (2008) Metabolism and cell biology of vitamin K. Thromb Haemost 100(4): 530-547.
34. Shiloh Y (2008) The land of Cush and Ethiopian Jewry. Available: http://www. biu. ac. il/JH/Parasha/eng/noah/shil. html. Accessed 2011 Jan 6.
35. Shuen AY, Wong BY, Fu L, Selby R, Cole DE (2012) Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin Biochem 45(6): 397-401. doi: 10. 1016/j. clinbiochem. 2012. 01. 002.
36. Skorecki K, Selig S, Blazer S, Bradman R, Bradman N, Waburton PJ, Ismajlowicz M, Hammer MF (1997) Y chromosomes of Jewish priests. Nature 385(6611): 32. doi: 10. 1038/385032a0.
37. Tabachnikov S, Aklillu E, Masimirembwa C, Maimbo M, Ken-Dror G, Dvoskin I, Cohen Y, Rechavi G, Amariglio N, Loebstein R, Kurnik D, Halkin H, Gak E (2010) Tracing of the Jewish-Ashkenazi mutation to ancient African populations. Abstract of Frontiers in Genetics VI The Genetic Society of Israel Annual Meeting 2010 Weizmann Institute of Science, Israel, p 112.
38. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2): 101-110.
39. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE (2005) Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 15(10): 687-691.
40. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4): 784-792. doi: 10. 1182/blood-2008-04-149070.
41. Watzka M, Geisen C, Bevans CG, Sittinger K, Spohn G, Rost S, Seifried E, Muller CR, Oldenburg J (2011) Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 9(1): 109-118. doi: 10. 1111/j. 1538-7836. 2010. 04095. x.